<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980276</url>
  </required_header>
  <id_info>
    <org_study_id>NUIG-2016-01</org_study_id>
    <nct_id>NCT02980276</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of the Effectiveness of Metformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus</brief_title>
  <acronym>EMERGE</acronym>
  <official_title>A Randomised Placebo Controlled Trial of the Effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Ireland, Galway, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Research Board, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HRB Clinical Research Facility Galway, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cork University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College Hospital Galway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University of Ireland, Galway, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the EMERGE trial is to determine whether metformin + usual care,
      compared to placebo + usual care (introduced at the time of initial diagnosis of GDM),
      reduces a) the need for insulin use, or hyperglycemia (primary outcome measure); b) excessive
      maternal weight gain; c) maternal and neonatal morbidities and, d) cost of treatment for
      women with Gestational Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Initiation/Fasting Glucose</measure>
    <time_frame>Change from Gestational Weeks 32 and 38</time_frame>
    <description>The primary efficacy outcome is a composite of:
Insulin initiation (Yes/No)
Fasting glucose value &lt;/=5.1 mmol/l and &gt;5.1 mmol/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Insulin Initiation</measure>
    <time_frame>Time to Insulin Initiation, from date of randomization until the date delivery, assessed up to 40 weeks</time_frame>
    <description>Time to Insulin Initiation, from date of randomization until the date delivery, assessed up to 40 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Morbidity at Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of women with maternal morbidity at delivery that is related to treatment (e.g. hypertensive disorders, antepartum/postpartum haemorrhage, polyhydroaminos)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Mode of delivery (e.g. vaginal, cesarean)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Gestational weeks at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum glucose status, insulin resistance, and metabolic syndrome</measure>
    <time_frame>12 weeks post-partum</time_frame>
    <description>Number of women with abnormal glucose values/insulin resistance/metabolic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-partum BMI</measure>
    <time_frame>12 weeks post-partum</time_frame>
    <description>Post-partum BMI in kg/m2 in participants between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Birth Weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Weight in kg at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal height and head circumference at delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Height in cm Head circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidities</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of neonates with respiratory distress, jaundice, congenital anomalies, need for neonatal care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hypoglyceamia</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of neonates with glucose &lt;2.6mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hypoglyceamia</measure>
    <time_frame>12 weeks post-partum</time_frame>
    <description>Number of neonates with glucose &lt;2.6mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Acceptibility</measure>
    <time_frame>4 weeks post-partum</time_frame>
    <description>Treatment acceptability determined by Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Rowan Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Treatment week 12</time_frame>
    <description>Quality of Life determined by EQ5D-5L Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post partum waist circumference</measure>
    <time_frame>12 weeks post partum</time_frame>
    <description>waist circumference in cm in participants between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational weight gain</measure>
    <time_frame>Change in weight from 24 weeks gestation until last visit before delivery</time_frame>
    <description>Change in weight (kg) from 24 weeks gestation until last visit before delivery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost effectiveness and budget impact of metformin treatment in addition to standard care</measure>
    <time_frame>24 weeks gestation to 12 weeks post-partum</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Women randomised to the metformin group will receive metformin 500mg OD, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Women randomised to the placebo group will receive 1 placebo tablet OD, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent

          2. Women aged 18-50

          3. Pregnancy gestation between 24 and 28 weeks

          4. Singleton pregnancy as determined by scan

          5. Positive diagnosis of Gestational Diabetes Mellitus on a OGTT according to IADPSG
             criteria if any one of the following are achieved: i) Fasting glucose &gt;/= 5.1mmol/l
             and &lt;7mmol/l, or ii) 1 hour post glucose load of &gt;/=10mmol/l, or iii) 2 hour post
             glucose load of &gt;/=8.5 mmol/l and &lt;11.1mmo/l

          6. Resident in the locality and intending to deliver within the trial site

        Exclusion Criteria:

          1. Women who have an established diagnosis of diabetes (Type 1, Type 2, Monogenic or
             secondary)

          2. Women with a fasting glucose &gt; 7mmol/l or a 2h value &gt; 11.1 mmol/l

          3. Multiple pregnancies (twins, triplets etc.) as determined by scan

          4. Known intolerance to metformin

          5. Known contraindication to the use of metformin which include: i) renal insufficiency
             (defined as serum creatinine of greater than 130 Âµmol/L or creatinine clearance &lt;60
             ml/min), ii) moderate to severe liver dysfunction (alkaline phosphatase and alanine
             aminotransferase greater than 3 times the upper limit of normal, iii) shock or sepsis,
             and iv) previous hypersensitivity to metformin

          6. Known fetal anomaly as determined by early or mid-trimester scan

          7. Known small for gestational age1 determined by early or mid-trimester scan

          8. Known gestational hypertension or pre-eclampsia or ruptured membranes

          9. Subjects who have a history of drug or alcohol use that, in the opinion of the
             investigator, would interfere with adherence to study requirements

         10. Women with significant gastrointestinal problems such as severe vomiting, Crohn's
             disease or colitis which will inadvertently affect absorption of the study drug

         11. Women with congestive heart failure or history of congestive heart failure

         12. Women with serious mental illness which would affect adherence to study medication or
             compliance with study protocol in the opinion of the investigator

         13. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. Fidelma Dunne</last_name>
    <phone>003539149</phone>
    <phone_ext>5074</phone_ext>
    <email>fidelma.dunne@nuigalway.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prof. Louise Kenny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Fidelma Dunne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Ireland, Galway, Ireland</investigator_affiliation>
    <investigator_full_name>Fidelma Dunne</investigator_full_name>
    <investigator_title>Prof. Fidelma Dunne</investigator_title>
  </responsible_party>
  <keyword>Gestational Diabetes</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

